U.S. markets close in 5 hours 15 minutes
  • S&P 500

    4,244.04
    -11.11 (-0.26%)
     
  • Dow 30

    34,240.71
    -153.04 (-0.44%)
     
  • Nasdaq

    14,089.59
    -84.55 (-0.60%)
     
  • Russell 2000

    2,310.42
    -15.72 (-0.68%)
     
  • Crude Oil

    71.74
    +0.86 (+1.21%)
     
  • Gold

    1,862.30
    -3.60 (-0.19%)
     
  • Silver

    27.73
    -0.31 (-1.10%)
     
  • EUR/USD

    1.2123
    0.0000 (-0.00%)
     
  • 10-Yr Bond

    1.5060
    +0.0050 (+0.33%)
     
  • GBP/USD

    1.4076
    -0.0032 (-0.22%)
     
  • USD/JPY

    110.1300
    +0.0690 (+0.06%)
     
  • BTC-USD

    40,062.58
    -746.52 (-1.83%)
     
  • CMC Crypto 200

    998.05
    -12.55 (-1.24%)
     
  • FTSE 100

    7,174.04
    +27.36 (+0.38%)
     
  • Nikkei 225

    29,441.30
    +279.50 (+0.96%)
     

The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of FGEN, EBS and CCIV

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·4 min read
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

NEW YORK, NY / ACCESSWIRE / May 5, 2021 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to participate in the suit. If you suffered a loss, you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff.

FibroGen, Inc. (NASDAQ:FGEN)
Class Period: November 8, 2019 - April 6, 2021
Lead Plaintiff Deadline: June 11, 2021

The FGEN lawsuit alleges that throughout the class period, FibroGen, Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) the Company's prior disclosures of U.S. primary cardiovascular safety analyses from the roxadustat Phase 3 program for the treatment of anemia certain safety analyses submitted in connection with CKD included post-hoc changes to the stratification factors; (ii) FibroGen's analyses with the pre-specified stratification factors result in higher hazard ratios (point estimates of relative risk) and 95% confidence intervals; (iii) based on these analyses the Company could not conclude that roxadustat reduces the risk of (or is superior to) MACE+ in dialysis, and MACE and MACE+ in incident dialysis compared to epoetin-alfa; (iv) as a result, the Company faced significant uncertainty that its NDA for roxadustat as a treatment for anemia of CKD would be approved by the FDA; and (v) as a result of the foregoing, Defendants' statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Learn about your recoverable losses in FGEN: http://www.kleinstocklaw.com/pslra-1/fibrogen-inc-loss-submission-form?id=15498&from=1

Emergent Biosolutions Inc. (NYSE:EBS)
Class Period: July 6, 2020 - March 31, 2021
Lead Plaintiff Deadline: June 18, 2021

The complaint alleges that throughout the class period Emergent Biosolutions Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) Emergent's Baltimore plant had a history of manufacturing issues increasing the likelihood for massive contaminations; (ii) these longstanding contamination risks and quality control issues at Emergent's facility led to a string of FDA citations; (iii) the Company previously had to discard the equivalent of millions of doses of COVID-19 vaccines after workers at the Baltimore plant deviated from manufacturing standards; and (iv) as a result of the foregoing, Defendants' public statements about Emergent's ability and capacity to mass manufacture multiple COVID-19 vaccines at its Baltimore manufacturing site were materially false and/or misleading and/or lacked a reasonable basis.

Learn about your recoverable losses in EBS: http://www.kleinstocklaw.com/pslra-1/emergent-biosolutions-inc-loss-submission-form?id=15498&from=1

Churchill Capital Corp IV (NYSE:CCIV)
Class Period: January 11, 2021 - February 22, 2021
Lead Plaintiff Deadline: June 18, 2021

Throughout the class period, Churchill Capital Corp IV allegedly made materially false and/or misleading statements and/or failed to disclose that: (1) Lucid was not prepared to deliver vehicles by spring of 2021; (2) Lucid was projecting a production of 557 vehicles in 2021 instead of the 6,000 vehicles touted in the run-up to the merger with Churchill; and (3) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages.

Learn about your recoverable losses in CCIV: http://www.kleinstocklaw.com/pslra-1/churchill-capital-corp-iv-loss-submission-form?id=15498&from=1

Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. If you suffered a loss during the class period and wish to obtain additional information, please contact J. Klein, Esq. by telephone at 212-616-4899 or visit the webpages provided.

J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
J. Klein, Esq.
Empire State Building
350 Fifth Avenue
59th Floor
New York, NY 10118
jk@kleinstocklaw.com
Telephone: (212) 616-4899
Fax: (347) 558-9665
www.kleinstocklaw.com

SOURCE: The Klein Law Firm



View source version on accesswire.com:
https://www.accesswire.com/644798/The-Klein-Law-Firm-Reminds-Investors-of-Class-Actions-on-Behalf-of-Shareholders-of-FGEN-EBS-and-CCIV